Zydus and TLC sign agreement to market Liposomal Amphotericin B in India
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The company also plans to register the similar range of products in the neighbouring countries.
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.
Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of USD 56 million in the U.S.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Subscribe To Our Newsletter & Stay Updated